Logo Logo
Switch Language to German

Herzog, Julia; Ehrlich, Sandra M.; Pfitzer, Lisa; Liebl, Johanna; Fröhlich, Thomas; Arnold, Georg J.; Mikulits, Wolfgang; Haider, Christine; Vollmar, Angelika M. and Zahler, Stefan (2016): Cyclin-dependent kinase 5 stabilizes hypoxia-inducible factor-1 alpha: a novel approach for inhibiting angiogenesis in hepatocellular carcinoma. In: Oncotarget, Vol. 7, No. 19: pp. 27108-27121

Full text not available from 'Open Access LMU'.


We recently introduced CDK5 as target in HCC, regulating DNA damage response. Based on this and on our previous knowledge about vascular effects of CDK5, we investigated the role of CDK5 in angiogenesis in HCC, one of the most vascularized tumors. We put a special focus on the transcription factor HIF-1 alpha, a master regulator of tumor angiogenesis. The interaction of CDK5 with HIF-1 alpha was tested by Western blot, PCR, reporter gene assay, immunohistochemistry, kinase assay, co-immunoprecipitation, mass spectrometry, and mutation studies. In vivo, different murine HCC models, were either induced by diethylnitrosamine or subcutaneous injection of HUH7 or HepG2 cells. The correlation of vascular density and CDK5 was assessed by immunostaining of a microarray of liver tissues from HCC patients. Inhibition of CDK5 in endothelial or HCC cells reduced HIF-1 alpha levels in vitro and in vivo, and transcription of HIF-1 alpha target genes (VEGFA, VEGFR1, EphrinA1). Mass spectrometry and site directed mutagenesis revealed a stabilizing phosphorylation of HIF-1 alpha at Ser687 by CDK5. Vascular density was decreased in murine HCC models by CDK5 inhibition. In conclusion, inhibiting CDK5 is a multi-modal systemic approach to treat HCC, hitting angiogenesis, as well as the tumor cells themselves.

Actions (login required)

View Item View Item